<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423826</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000518230</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2006-059</secondary_id>
    <secondary_id>WSU-112506MP2F</secondary_id>
    <nct_id>NCT00423826</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease</brief_title>
  <official_title>A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor&#xD;
      umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.&#xD;
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells may replace the patient's immune cells and help destroy any remaining cancer or&#xD;
      abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can&#xD;
      also make an immune response against the body's normal cells. Giving tacrolimus and&#xD;
      mycophenolate mofetil before the transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well umbilical cord blood stem cell transplant&#xD;
      works in treating patients with hematologic cancer or other disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of double umbilical cord blood stem cell transplantation using a&#xD;
           conditioning regimen comprising lower doses of busulfan and fludarabine phosphate and&#xD;
           low-dose total body irradiation, in terms of stem cell engraftment at 60 days post&#xD;
           transplantation, in patients with hematologic cancer or other diseases.&#xD;
&#xD;
        -  Determine the merits of conducting a larger, comparative study of this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine mortality within 100 days of transplantation in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Reduced-intensity conditioning regimen: Patients receive busulfan IV over 3 hours on&#xD;
           days -9 to -8 and fludarabine phosphate IV on days -7 to -3. Patients then undergo&#xD;
           low-dose total body irradiation on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive tacrolimus IV twice daily and&#xD;
           mycophenolate orally or IV three times daily beginning on day -3.&#xD;
&#xD;
        -  CNS prophylaxis and/or treatment: Patients with a history of CNS involvement receive&#xD;
           prophylactic cytarabine (Ara-C) intrathecally (IT) prior to transplant. Patients also&#xD;
           undergo lumbar puncture (LP) to test for active CNS disease. Patients with cerebrospinal&#xD;
           fluid positive for leukemia receive Ara-C IT every 2-3 days until a repeat LP shows no&#xD;
           remaining leukemic cells. Three days after the last LP and after one final dose of&#xD;
           Ara-C, patients begin the conditioning regimen.&#xD;
&#xD;
        -  Double umbilical cord blood (UCB) donor stem cell transplantation (SCT): Patients&#xD;
           undergo double UCB donor SCT on day 0.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Precancerous Condition</condition>
  <condition>Secondary Myelofibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3 mg/kg intravenously over 3 hours</description>
    <other_name>Busulfex®</other_name>
    <other_name>Myleran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.</description>
    <other_name>DepoCyt(TM)</other_name>
    <other_name>Liposomal Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine phosphate</intervention_name>
    <description>25 mg/M2/day IV</description>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Orally at the dose of 1 gm every 8 hours.</description>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>0.015 mg/kg IV every 12 hours by continuous infusion.</description>
    <other_name>Advagraf</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>10 days post drug intervention</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>10 days post drug intervention</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>10 days post drug intervention</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Acute myeloid leukemia meeting the following criteria:&#xD;
&#xD;
                    -  M0-M7 histologic subtypes by French-American-British classification&#xD;
&#xD;
                    -  Previously treated disease&#xD;
&#xD;
                    -  Meets 1 of the following criteria:&#xD;
&#xD;
                         -  Persistent disease as evidenced by 5-30% persistent blasts in bone&#xD;
                            marrow after induction or salvage therapy&#xD;
&#xD;
                         -  In second or subsequent complete remission (CR)&#xD;
&#xD;
                         -  In first CR with 1 of the following high-risk features:&#xD;
&#xD;
                              -  Philadelphia chromosome present&#xD;
&#xD;
                              -  Noncore-binding factor type of chromosomal abnormalities&#xD;
&#xD;
               -  Myelodysplastic syndromes with 1 of the following International Prognostic&#xD;
                  Scoring System (IPSS) scores:&#xD;
&#xD;
                    -  Intermediate-1&#xD;
&#xD;
                    -  Intermediate-2&#xD;
&#xD;
                    -  High-risk score with transfusion dependence&#xD;
&#xD;
               -  Chronic myelogenous leukemia meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In accelerated or blastic phase&#xD;
&#xD;
                    -  Failed prior imatinib mesylate therapy&#xD;
&#xD;
               -  Acute lymphoblastic leukemia meeting 1 of the following criteria:&#xD;
&#xD;
                    -  In first CR with any of the following high-risk features:&#xD;
&#xD;
                         -  Philadelphia chromosome present&#xD;
&#xD;
                         -  Translocation t(4;11) present&#xD;
&#xD;
                         -  WBC &gt; 30,000/mm³ (adult patients)&#xD;
&#xD;
                         -  More than 4 weeks from initiation of treatment was required to achieve&#xD;
                            CR (adult patients)&#xD;
&#xD;
                         -  DNA index of near haploid (N=23 chromosomes) (pediatric patients)&#xD;
&#xD;
                    -  In second or subsequent CR&#xD;
&#xD;
                    -  Persistent disease as evidenced by 5-20% persistent blasts in bone marrow&#xD;
                       after induction or salvage therapy&#xD;
&#xD;
               -  Hodgkin's or non-Hodgkin's lymphoma meeting the following criteria:&#xD;
&#xD;
                    -  Recurrent or refractory disease&#xD;
&#xD;
                    -  Tumor ≤ 5 cm in diameter&#xD;
&#xD;
               -  Myeloma or plasma cell neoplasm meeting 1 of the following staging criteria:&#xD;
&#xD;
                    -  Stage III at presentation&#xD;
&#xD;
                    -  Stage I-II at presentation&#xD;
&#xD;
                         -  Not responding OR progressed after first-line therapy&#xD;
&#xD;
               -  Chronic lymphocytic leukemia or Waldenstrom's macroglobulinemia with refractory&#xD;
                  or progressive disease after first-line therapy&#xD;
&#xD;
          -  No 5-6/6 HLA-matched related or 7-8/8 HLA-matched unrelated marrow or peripheral blood&#xD;
             stem cell donor available&#xD;
&#xD;
          -  No single 4-6/6 HLA-A, -B, or -DRB1-matched umbilical cord blood unit ≥ 3.5 x 10^7&#xD;
             nucleated cells/kg available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky or Lansky PS 70-100%&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and during study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Bilirubin &lt; 3.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Cardiac ejection fraction &gt; 50% by echocardiogram OR shortening fraction &gt; 27%&#xD;
&#xD;
          -  No uncontrolled symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  FEV_1 &gt; 50% of normal&#xD;
&#xD;
          -  Forced vital capacity &gt; 50% of normal&#xD;
&#xD;
          -  DLCO normal&#xD;
&#xD;
          -  Oxygen saturation &gt; 92% on room air (for patients &lt; 5 years of age)&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to busulfan and fludarabine phosphate&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent surgery&#xD;
&#xD;
          -  At least 4 weeks since prior and no other concurrent investigational or commercial&#xD;
             agents or therapies for the malignancy, including chemotherapy, biologic therapy, or&#xD;
             radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Voravit Ratanatharathorn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 16, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Voravit Ratanatharathorn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>extramedullary plasmacytoma</keyword>
  <keyword>isolated plasmacytoma of bone</keyword>
  <keyword>monoclonal gammopathy of undetermined significance</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>childhood acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>secondary myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

